97 related articles for article (PubMed ID: 32779238)
1. PD-1 and PD-L1 expression in Kaposi sarcoma: A comparative study according to the pathological stage and clinical characteristics.
Kim YJ; Jung CJ; Won CH; Chang SE; Lee MW; Choi JH; Lee WJ
J Cutan Pathol; 2021 Feb; 48(2):221-228. PubMed ID: 32779238
[TBL] [Abstract][Full Text] [Related]
2. Stage-related PD-L1 expression in Kaposi sarcoma tumor microenvironment.
Joest B; Kempf W; Berisha A; Peyk P; Tronnier M; Mitteldorf C
J Cutan Pathol; 2020 Oct; 47(10):888-895. PubMed ID: 32310306
[TBL] [Abstract][Full Text] [Related]
3. Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors.
Sampedro-Núñez M; Serrano-Somavilla A; Adrados M; Cameselle-Teijeiro JM; Blanco-Carrera C; Cabezas-Agricola JM; Martínez-Hernández R; Martín-Pérez E; Muñoz de Nova JL; Díaz JÁ; García-Centeno R; Caneiro-Gómez J; Abdulkader I; González-Amaro R; Marazuela M
Sci Rep; 2018 Dec; 8(1):17812. PubMed ID: 30546030
[TBL] [Abstract][Full Text] [Related]
4. PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer.
Kawahara T; Ishiguro Y; Ohtake S; Kato I; Ito Y; Ito H; Makiyama K; Kondo K; Miyoshi Y; Yumura Y; Hayashi N; Hasumi H; Osaka K; Muraoka K; Izumi K; Teranishi JI; Uemura H; Yao M; Nakaigawa N
BMC Urol; 2018 Nov; 18(1):97. PubMed ID: 30400941
[TBL] [Abstract][Full Text] [Related]
5. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.
Kiyasu J; Miyoshi H; Hirata A; Arakawa F; Ichikawa A; Niino D; Sugita Y; Yufu Y; Choi I; Abe Y; Uike N; Nagafuji K; Okamura T; Akashi K; Takayanagi R; Shiratsuchi M; Ohshima K
Blood; 2015 Nov; 126(19):2193-201. PubMed ID: 26239088
[TBL] [Abstract][Full Text] [Related]
6. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
Del C Monroig-Bosque P; Driver B; Morales-Rosado JA; Deavers M; Tacha D; Bernicker E; Cagle PT; Miller RA
Arch Pathol Lab Med; 2018 Nov; 142(11):1388-1393. PubMed ID: 29431467
[TBL] [Abstract][Full Text] [Related]
7. Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.
Spurny C; Kailayangiri S; Jamitzky S; Altvater B; Wardelmann E; Dirksen U; Hardes J; Hartmann W; Rossig C
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28868758
[TBL] [Abstract][Full Text] [Related]
8. Expression of Programmed Cell Death Proteins in Kaposi Sarcoma and Cutaneous Angiosarcoma.
Gambichler T; Koim S; Wrobel M; Käfferlein HU; Brüning T; Stockfleth E; Becker JC; Lang K
J Immunother; 2020 Jun; 43(5):169-174. PubMed ID: 32224717
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 Copy Number Variation Does Not Correlate With PD-L1 Expression or Response to Anti-PD-1 Immunotherapy In Patients With Advanced Melanomas.
Pérottet J; Le Goff E; Legoupil D; Quéré G; Schick U; Marcorelles P; Uguen A
Appl Immunohistochem Mol Morphol; 2020 Feb; 28(2):161-165. PubMed ID: 32044885
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma.
Maekawa N; Konnai S; Okagawa T; Nishimori A; Ikebuchi R; Izumi Y; Takagi S; Kagawa Y; Nakajima C; Suzuki Y; Kato Y; Murata S; Ohashi K
PLoS One; 2016; 11(6):e0157176. PubMed ID: 27276060
[TBL] [Abstract][Full Text] [Related]
11. Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma.
Hollander P; Amini RM; Ginman B; Molin D; Enblad G; Glimelius I
PLoS One; 2018; 13(9):e0204870. PubMed ID: 30261066
[TBL] [Abstract][Full Text] [Related]
12. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
Drakes ML; Mehrotra S; Aldulescu M; Potkul RK; Liu Y; Grisoli A; Joyce C; O'Brien TE; Stack MS; Stiff PJ
J Ovarian Res; 2018 May; 11(1):43. PubMed ID: 29843813
[TBL] [Abstract][Full Text] [Related]
13. PD-1/PD-L1 expressions in medullary thyroid carcinoma: Clinicopathologic and prognostic analysis of Chinese population.
Bi Y; Ren X; Bai X; Meng Y; Luo Y; Cao J; Zhang Y; Liang Z
Eur J Surg Oncol; 2019 Mar; 45(3):353-358. PubMed ID: 30528043
[TBL] [Abstract][Full Text] [Related]
14. Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma.
Owen D; Chu B; Lehman AM; Annamalai L; Yearley JH; Shilo K; Otterson GA
J Thorac Oncol; 2018 Aug; 13(8):1204-1212. PubMed ID: 29702286
[TBL] [Abstract][Full Text] [Related]
15. A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma.
Steuer CE; Griffith CC; Nannapaneni S; Patel MR; Liu Y; Magliocca KR; El-Deiry MW; Cohen C; Owonikoko TK; Shin DM; Chen ZG; Saba NF
Mol Cancer Ther; 2018 Mar; 17(3):710-716. PubMed ID: 29440293
[TBL] [Abstract][Full Text] [Related]
16. Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.
Yu H; Chen Z; Ballman KV; Watson MA; Govindan R; Lanc I; Beer DG; Bueno R; Chirieac LR; Chui MH; Chen G; Franklin WA; Gandara DR; Genova C; Brovsky KA; Joshi MM; Merrick DT; Richards WG; Rivard CJ; Harpole DH; Tsao MS; van Bokhoven A; Shepherd FA; Hirsch FR
J Thorac Oncol; 2019 Jan; 14(1):25-36. PubMed ID: 30253973
[TBL] [Abstract][Full Text] [Related]
17. The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance and prognostic value: a study of 89 consecutive cases.
Ren Y; Lv Q; Yue W; Liu B; Zou Z
Melanoma Res; 2020 Feb; 30(1):85-101. PubMed ID: 31095042
[TBL] [Abstract][Full Text] [Related]
18. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
19. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 Expression is Associated With Poor Prognosis in Renal Cell Carcinoma.
Carlsson J; Sundqvist P; Kosuta V; Fält A; Giunchi F; Fiorentino M; Davidsson S
Appl Immunohistochem Mol Morphol; 2020 Mar; 28(3):213-220. PubMed ID: 31058656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
